摘要
目的探讨依达拉奉右莰醇联合溶栓治疗对急性缺血性脑卒中患者的神经功能保护作用及其作用机制。方法选择2020年12月至2022年1月西安市第三医院神经内科收治的90例急性缺血性脑卒中患者展开研究,按随机数表法分为观察组和对照组各45例。两组患者均接受静脉溶栓治疗,对照组患者在溶栓后使用依达拉奉注射液治疗,观察组患者溶栓后则使用依达拉奉右莰醇注射用浓溶液治疗,两组均治疗两周。比较两组患者治疗两周后的临床疗效,治疗前及治疗两周后的美国国立卫生研究院卒中量表(NIHSS)评分、巴氏量表(Barthel指数)、血清谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平及治疗期间的不良反应发生情况。结果治疗后,观察组患者的临床疗效总有效率为91.11%,明显高于对照组的73.33%,差异有统计学意义(P<0.05);治疗后,观察组患者的NIHSS评分为(7.90±1.34)分,明显低于对照组的(9.42±1.68)分,Barthel指数为(67.14±5.18)分,明显高于对照组的(62.89±4.67)分,差异均有统计学意义(P<0.05);治疗后,观察组患者的血清GSH-Px、SOD水平分别为(234.09±21.57)mg/L、(95.23±17.45)U/mL,明显高于对照组的(205.63±18.32)mg/L、(79.56±14.18)U/mL,血清MDA、TNF-α、IL-1β水平分别为(4.65±0.89)μmol/L、(86.52±15.40)ng/L、(86.52±15.40)pg/mL,明显低于对照组的(6.42±1.10)μmol/L、(113.67±16.05)ng/L、(288.51±31.27)pg/mL,差异均有统计学意义(P<0.05);两组患者治疗期间均无明显不良反应发生。结论依达拉奉右莰醇联合溶栓治疗对急性缺血性脑卒中患者的效果显著,可有效促进患者神经功能恢复,其机制可能与缓解氧化应激损伤、抑制炎症反应等相关。
Objective To investigate the protective effect of edaravone dexcamphenol combined with thrombolytic therapy on neurological function in patients with acute ischemic stroke and its mechanism.Methods A total of 90 patients with acute ischemic stroke admitted to Department of Neurology,Xi'an Third Hospital from December 2020 to January 2022 were selected and divided into an observation group and a control group by random number table method,with 45 patients in each group.Based on intravenous thrombolytic therapy,the patients in the control group were treated with edaravone injection after thrombolytic therapy,and patients in the observation group were treated with concentrated solution for edaravone dexcamphenol injection after thrombolytic therapy,both for 2 weeks.The clinical efficacy at 2 weeks after treatment,the National Institutes of Health Stroke Scale(NIHSS)score,Barthel Scale(Barthel Index),serum glutathione peroxidase(GSH-Px),superoxide dismutase(SOD),malondialdehyde(MDA),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β)before treatment and at 2 weeks after treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results After treatment,the total effective rate in the observation group was 91.11%,which was significantly higher than 73.33%of the control group(P<0.05);after treatment,the NIHSS score in observation group was(7.90±1.34)points,which was significantly lower than(9.42±1.68)points of the control group,and the Barthel index was(67.14±5.18)points,which was significantly higher than(62.89±4.67)points of control group,with statistically significant differences(P<0.05).After treatment,the serum GSH-Px and SOD levels in the observation group were(234.09±21.57)mg/L and(95.23±17.45)U/mL,which were significantly higher than(205.63±18.32)mg/L and(79.56±14.18)U/mL of the control group;the serum MDA,TNF-α,and IL-1βlevels were(4.65±0.89)μmol/L,(86.52±15.40)ng/L,(86.52±15.40)pg/mL,which were significantly lower than(6.42±1.10)μmol/L,(113.67±1
作者
陈小妮
谭会会
陈蕊
CHEN Xiao-ni;TAN Hui-hui;CHEN Rui(Department of Neurology,Xi'an Third Hospital,Xi'an 710021,Shaanxi,CHINA)
出处
《海南医学》
CAS
2023年第3期314-318,共5页
Hainan Medical Journal
基金
陕西省青年培育项目(编号:2020qn06)。
关键词
急性缺血性脑卒中
溶栓
依达拉奉右莰醇
氧化应激
炎症因子
疗效
不良反应
Acute ischemic stroke
Thrombolysis
Edaravone dexcamphenol
Oxidative stress
Inflammatory factors
Curative effect
Adverse reactions
